Eli Lilly’s Retatrutide Achieves Up to 30% Weight Loss in Phase-3 Trial

Eli Lilly’s Retatrutide Achieves Up to 30% Weight Loss in Phase-3 Trial

Business Health

Eli Lilly reported that its experimental drug retatrutide produced an average 25% weight loss after 80 weeks in a large phase-3 trial, and also lowered the incidence of knee pain and sleep-apnea events, according to a presentation in Milan, Italy. Earlier reports described the drug’s effects in the same trial. Ars Technica said participants lost an average 25% of body weight after 80 weeks, with some achieving up to 30% loss and improvements in several obesity-related health measures.

The Guardian noted that the double-blind study showed up to 19% weight loss and better blood-sugar control in people with obesity and type 2 diabetes. NBC News added that some participants lost up to 23% of body weight, equivalent to about 60 pounds, and that the company plans to file for FDA approval next year.

Actors

Eli Lilly European Association for the Study of Diabetes The Lancet

Locations

Milan, Italy

Fact Check

How these metrics work
Verdict: Partial Confidence: 45% Claims: 2
At a glance

The claim that on September 29, 2026, the experimental drug retatrutide helped participants with obesity and type 2 diabetes lose up to 19% of body weight and improve blood-sugar control in a large double-blind study was partially confirmed. The claim that late-stage trials showed retatrutide helped participants with type 2 diabetes lose up to 23% of body weight and improve blood-sugar control on September 29, 2026, had insufficient evidence.

Sign in or subscribe to unlock the full breakdown: claims, sources, and validations.

Sign up Sign in

This section contains an automated verification of claims against external sources and may contain inaccuracies.

Articles

October 03, 2026
1 total
Experimental Drug Retatrutide Shows Up to 30% Weight Loss in Phase 3 Trial
Experimental Drug Retatrutide Shows Up to 30% Weight Loss in Phase 3 Trial

ScienceAlert • 03 Oct 01:02

In a large phase-3 study, the weekly injection retatrutide led to an average weight loss of 25% after 80 weeks at its highest dose, with additional reductions in knee pain and sleep-apnea events.

Credibility 78% Manip. 8% Center
October 02, 2026
1 total
Eli Lilly and Novo advance amylin-based therapies to complement GLP-1 obesity drugs
Eli Lilly and Novo advance amylin-based therapies to complement GLP-1 obesity drugs

CNBC • 02 Oct 15:13

Eli Lilly and Novo are testing amylin-targeting drugs, both alone and in combination with existing GLP-1 treatments, aiming to improve weight-loss outcomes for patients with obesity and type 2 diabetes.

Credibility 71% Manip. 9% Center
October 01, 2026
1 total
Eli Lilly's retatrutide shows significant weight loss and blood sugar improvements in Phase 3 trial
Eli Lilly's retatrutide shows significant weight loss and blood sugar improvements in Phase 3 trial

New York Post • 01 Oct 14:18

In a Phase 3 study, participants taking the lowest dose of retatrutide lost about 12.7% of body weight and saw reductions in blood sugar, while higher doses produced greater effects.

Credibility 72% Manip. 32% Center
September 30, 2026
1 total
Eli Lilly reports 23.3% average weight loss with amylin-Zepbound combo in diabetic obesity trial
Eli Lilly reports 23.3% average weight loss with amylin-Zepbound combo in diabetic obesity trial

Fierce Biotech • 30 Sep 17:52

In a phase-2 study, Eli Lilly's amylin-Zepbound combination achieved a 23.3% average weight loss and improved A1C in adults with obesity or overweight and type-2 diabetes, prompting plans for phase-3 trials.

Credibility 72% Manip. 8% Center
September 29, 2026
3 total
Triple-hormone drug retatrutide shows up to 30% weight loss in late-stage trial
Triple-hormone drug retatrutide shows up to 30% weight loss in late-stage trial

Ars Technica • 29 Sep 22:30

In a phase-III study, Eli Lilly's retatrutide led participants to lose an average of 25% of body weight after 80 weeks, with further reductions after 104 weeks, while also improving several obesity-related health measures.

Credibility 78% Manip. 12% Center
Eli Lilly's experimental drug retatrutide yields up to 60-pound weight loss in type 2 diabetes trial
Eli Lilly's experimental drug retatrutide yields up to 60-pound weight loss in type 2 diabetes trial

NBC News • 29 Sep 22:01

Late-stage trials showed retatrutide helped participants with type 2 diabetes lose up to 23% of body weight and improve blood-sugar control, prompting plans for FDA filing next year.

Credibility 78% Manip. 12% Center
New obesity drug retatrutide shows significant weight loss and metabolic benefits in phase 3 trial
New obesity drug retatrutide shows significant weight loss and metabolic benefits in phase 3 trial

The Guardian • 29 Sep 22:01

In a large double-blind study, the experimental drug retatrutide helped participants with obesity and type 2 diabetes lose up to 19% of body weight and improve blood-sugar control, though it is not yet approved.

Credibility 78% Manip. 10% Center

Related events